{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+protein&page=100",
    "query": {
      "intervention": "Normal protein",
      "page": 100
    },
    "page_size": 10
  },
  "pagination": {
    "page": 100,
    "page_size": 10,
    "total_count": 2509,
    "total_pages": 251,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+protein&page=101&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Normal+protein&page=99&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T16:44:46.682Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00146562",
      "title": "Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Stage I Breast Cancer",
        "Stage II Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Darbepoetin Alfa",
          "type": "DRUG"
        },
        {
          "name": "Pegfilgrastim",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harold J. Burstein, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 135,
      "start_date": "2003-07",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2023-08-02",
      "last_synced_at": "2026-11-11T16:44:46.682Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Lowell, Massachusetts • Peabody, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Lowell",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00146562"
    },
    {
      "nct_id": "NCT02476786",
      "title": "Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Cancer of Breast",
        "Breast Neoplasms",
        "Cancer of the Breast"
      ],
      "interventions": [
        {
          "name": "FACT-B",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Goserelin",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        },
        {
          "name": "Archived tissue collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "70 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "2017-01-17",
      "completion_date": "2032-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-11-11T16:44:46.682Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02476786"
    },
    {
      "nct_id": "NCT04623086",
      "title": "Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Insulin Degludec",
          "type": "DRUG"
        },
        {
          "name": "Insulin Glargine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 59,
      "start_date": "2020-02-14",
      "completion_date": "2023-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-11-11T16:44:46.682Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04623086"
    },
    {
      "nct_id": "NCT04743661",
      "title": "131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Medulloblastoma",
        "Recurrent Ependymoma"
      ],
      "interventions": [
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Omburtamab I-131",
          "type": "DRUG"
        },
        {
          "name": "Liothyronine",
          "type": "DRUG"
        },
        {
          "name": "SSKI",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Antipyretic",
          "type": "DRUG"
        },
        {
          "name": "Antihistamine",
          "type": "DRUG"
        },
        {
          "name": "anti-emetics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pediatric Brain Tumor Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 62,
      "start_date": "2022-04-04",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-11-11T16:44:46.682Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • New York, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04743661"
    },
    {
      "nct_id": "NCT05987241",
      "title": "Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Muscle Invasive Bladder Urothelial Carcinoma",
        "Muscle Invasive Renal Pelvis Urothelial Carcinoma",
        "Muscle Invasive Ureter Urothelial Carcinoma",
        "Muscle Invasive Urethral Urothelial Carcinoma",
        "Stage II Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage IV Bladder Urothelial Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "cfDNA or ctDNA Measurement",
          "type": "OTHER"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cystoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Relatlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 992,
      "start_date": "2024-02-02",
      "completion_date": "2030-09-02",
      "has_results": false,
      "last_update_posted_date": "2026-11-06",
      "last_synced_at": "2026-11-11T16:44:46.682Z",
      "location_count": 495,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 374 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05987241"
    },
    {
      "nct_id": "NCT00004474",
      "title": "Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "Anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Bone marrow transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "Up to 59 Years"
      },
      "enrollment_count": 224,
      "start_date": "1998-09",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2018-03-12",
      "last_synced_at": "2026-11-11T16:44:46.682Z",
      "location_count": 4,
      "location_summary": "Buffalo, New York • Houston, Texas • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004474"
    },
    {
      "nct_id": "NCT00416624",
      "title": "Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia",
        "Leukemia",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Precancerous Condition",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "darbepoetin alfa",
          "type": "DRUG"
        },
        {
          "name": "epoetin alfa",
          "type": "DRUG"
        },
        {
          "name": "fatigue assessment and management",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 239,
      "start_date": "2007-05",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2017-02-10",
      "last_synced_at": "2026-11-11T16:44:46.682Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00416624"
    },
    {
      "nct_id": "NCT06483659",
      "title": "Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "Oxytocin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 152,
      "start_date": "2025-06-01",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-11-11T16:44:46.682Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06483659"
    },
    {
      "nct_id": "NCT00243646",
      "title": "Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "External beam radiation",
          "type": "RADIATION"
        },
        {
          "name": "Lupron",
          "type": "DRUG"
        },
        {
          "name": "Casodex",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "Schiffler Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 6,
      "start_date": "2004-08",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2016-04-14",
      "last_synced_at": "2026-11-11T16:44:46.682Z",
      "location_count": 3,
      "location_summary": "Seattle, Washington • Wheeling, West Virginia",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Wheeling",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00243646"
    },
    {
      "nct_id": "NCT07329088",
      "title": "Isoleucine Addition Treatment Effects in a Controlled Diet Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)",
        "Metabolic Syndrome (MetS)",
        "Obesity & Overweight"
      ],
      "interventions": [
        {
          "name": "L-Isoleucine",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Low-isoleucine diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Jean L. Fry",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2026-05-04",
      "completion_date": "2029-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-11-11T16:44:46.682Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07329088"
    }
  ]
}